Vaccine Platforms and Technologies

This note covers vaccine platforms not already treated in depth elsewhere on this site: conjugate vaccines and a further viral-vector example. The full live-attenuated/inactivated/subunit/viral-vector/mRNA taxonomy, and Covishield, Covaxin and GEMCOVAC-19 specifically, are covered in Microbes, Immunity and Modern Biotechnology.

A conjugate vaccine solves a specific problem: young children's immune systems ignore plain sugar coats

Many dangerous bacteria, including the Streptococcus pneumoniae strains that cause pneumonia, meningitis and sepsis, protect themselves with an outer capsule made of polysaccharide (sugar chains). A vaccine using that polysaccharide alone works reasonably well in adults, but a young child's immune system, which has not yet matured its full antibody-generating machinery, responds to plain polysaccharide antigens only weakly and, critically, without generating durable immune memory.

A conjugate vaccine solves exactly this problem by chemically linking that weak polysaccharide antigen to a carrier protein the immune system recognises strongly. The strong protein-driven response effectively "trains" the immune system to also mount a robust, memory-forming response against the attached polysaccharide, something the polysaccharide could never trigger by itself in a young child. The Pneumococcal Conjugate Vaccine (PCV), part of India's immunisation programme, works on exactly this principle, protecting children against pneumococcal pneumonia, meningitis and sepsis. Its wider use also reduces society's reliance on antibiotics to treat these infections after the fact, which is a genuine, if indirect, contribution to slowing antibiotic resistance, since preventing an infection outright removes the need to treat it at all.

A second real-world viral vector example, beyond Covishield

The viral vector platform, where a harmless virus is engineered to carry and deliver a target pathogen's genetic material, is not unique to Covishield's chimpanzee adenovirus. Sputnik V, Russia's COVID-19 vaccine, is also built on a viral vector platform, using human adenoviruses as its delivery vehicle rather than a chimpanzee one. Knowing that Sputnik V belongs to the same broad platform category as Covishield, despite being developed independently and using a different specific vector virus, is the kind of cross-country platform comparison this space gets tested on.

Quick revision points

• A conjugate vaccine links a weak polysaccharide antigen (from a bacterium's capsule) to a strong carrier protein, so a young child's immune system mounts a durable, memory-forming response it could not mount to the polysaccharide alone.
• PCV (Pneumococcal Conjugate Vaccine): a conjugate vaccine protecting against pneumococcal pneumonia, meningitis and sepsis; wider use reduces downstream antibiotic reliance.
• Sputnik V (Russia): a viral vector vaccine, using human adenoviruses, the same broad platform category as Covishield's chimpanzee adenovirus, just a different specific vector.
• The full vaccine-platform taxonomy (live attenuated, inactivated, subunit/toxoid, viral vector, mRNA) and India's own Covishield/Covaxin/GEMCOVAC-19 examples are covered in Microbes, Immunity and Modern Biotechnology.